Featured News

Congratulations to Celiac Disease Foundation research partner Takeda Pharmaceuticals and its Medical Director Dan Leffler on recent media attention for three potential celiac disease therapies.

U.S. News and World Report and HealthDay recently published an overview of celiac disease that breaks down causes, symptoms, and the importance of self-care. We appreciate these publications for raising awareness, which can help in accelerating diagnosis of celiac disease.

This year, we are proud to acknowledge the outpouring of support we received during the month of May.  

Today is the last day to receive Proud Sponsor King Arthur Baking Company product in exchange for a donation to the Celiac Disease Foundation! Join us in generating research funds for treatments and a cure.

During the month of May, the Celiac Disease Foundation is taking the opportunity to honor the advocacy efforts of our dedicated, inspiring celiac disease patient community.

During May, Celiac Disease Awareness Month, the Celiac Disease Foundation wants to take this opportunity to honor the advocacy efforts of our dedicated, inspiring celiac disease patient community.

DDW 2023 showcased some of the latest research and innovations in celiac disease. These included promising early results from four investigational medications currently being tested for the treatment of celiac disease, as well as CDF research conducted in partnership with Takeda and Adelphi Real World.

For a refreshing spring treat, try these lemon meringue snaps from Proud Sponsor Snyder’s – sure to hit the spot!

The Celiac Disease Foundation is teaming up with celiac disease associations and societies around the world to celebrate this day with the Shine a Light on Celiac campaign.

The ILLUMINATE Studies are phase 2 clinical research studies evaluating an investigational medication designed to reduce or eliminate the negative immune response to gluten in adults with celiac disease.